Publication:
Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation.

dc.contributor.authorde la Varga Martínez, Raquel
dc.contributor.authorRodríguez-Bayona, Beatriz
dc.contributor.authorAñez, Gustavo A
dc.contributor.authorMedina Varo, Fermín
dc.contributor.authorPérez Venegas, José J
dc.contributor.authorBrieva, José A
dc.contributor.authorRodríguez, Carmen
dc.date.accessioned2023-01-25T09:45:42Z
dc.date.available2023-01-25T09:45:42Z
dc.date.issued2017-05-23
dc.description.abstractDisturbances of plasma cell homeostasis and auto-antibody production are hallmarks of systemic lupus erythematosus. The aim of this study was to explore the presence of circulating anti-ENA and anti-dsDNA antibody-secreting cells, to determine their dependence on plasma cell-niche cytokines and to analyze their clinical value. The study was performed in SLE patients with serum anti-ENA and/or anti-dsDNA antibodies (n = 57). Enriched B-cell fractions and sorted antibody-secreting cells (CD19low CD38high ) were obtained from blood. dsDNA- and ENA-specific antibody-secreting cells were identified as cells capable of active auto-antibody production in culture. The addition of a combination of IL-6, IL-21, BAFF, APRIL, and CXCL12 to the cultures significantly augmented auto-antibody production and antibody-secreting cell proliferation, whereas it diminished apoptosis. The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic. Among patients with serum anti-dsDNA antibodies, the detection of circulating anti-dsDNA-antibody-secreting cells was associated with higher disease activity markers. In conclusion, auto-antibody production in response to plasma cell-niche cytokines that are usually at high levels in SLE patients is dependent on JAK/STAT-3 activation. Thus, patients with circulating anti-dsDNA antibody-secreting cells and active disease could potentially benefit from therapies targeting the JAK/STAT3 pathway.
dc.identifier.doi10.1002/eji.201646872
dc.identifier.essn1521-4141
dc.identifier.pmid28463395
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eji.201646872
dc.identifier.urihttp://hdl.handle.net/10668/11156
dc.issue.number7
dc.journal.titleEuropean journal of immunology
dc.journal.titleabbreviationEur J Immunol
dc.language.isoen
dc.organizationÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Juan Ramón Jiménez
dc.organizationAGS - Jerez, Costa Noroeste y Sierra de Cáidz
dc.page.number1211-1219
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subjectAnti-ENA
dc.subjectAnti-dsDNA
dc.subjectAntibody-secreting cells
dc.subjectCytokines
dc.subjectPlasma cell niche
dc.subjectSLE
dc.subjectSTAT-3
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Antinuclear
dc.subject.meshAntibody-Producing Cells
dc.subject.meshApoptosis
dc.subject.meshB-Cell Activating Factor
dc.subject.meshCell Proliferation
dc.subject.meshChemokine CXCL2
dc.subject.meshCyclic S-Oxides
dc.subject.meshDNA
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInterleukin-6
dc.subject.meshInterleukins
dc.subject.meshLupus Erythematosus, Systemic
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNitriles
dc.subject.meshPyrazoles
dc.subject.meshPyrimidines
dc.subject.meshSTAT3 Transcription Factor
dc.subject.meshTumor Necrosis Factor Ligand Superfamily Member 13
dc.subject.meshYoung Adult
dc.titleClinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number47
dspace.entity.typePublication

Files